UroGen Pharma (NASDAQ:URGN - Get Free Report) was upgraded by equities researchers at HC Wainwright from a "neutral" rating to a "buy" rating in a note issued to investors on Monday, MarketBeat reports. The brokerage currently has a $50.00 price objective on the stock. HC Wainwright's price target indicates a potential upside of 248.68% from the company's previous close.
Other equities research analysts have also issued reports about the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. Guggenheim restated a "buy" rating and issued a $30.00 price target (up from $15.00) on shares of UroGen Pharma in a research report on Friday. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday. Oppenheimer dropped their price target on UroGen Pharma from $36.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, June 3rd. Finally, Scotiabank upped their price target on UroGen Pharma from $23.00 to $47.00 and gave the company a "sector outperform" rating in a research report on Friday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, UroGen Pharma currently has a consensus rating of "Buy" and a consensus target price of $32.86.
Get Our Latest Stock Analysis on UroGen Pharma
UroGen Pharma Price Performance
NASDAQ:URGN traded up $2.31 during trading hours on Monday, hitting $14.34. 8,782,260 shares of the stock were exchanged, compared to its average volume of 1,013,418. UroGen Pharma has a 52-week low of $3.42 and a 52-week high of $19.01. The firm's fifty day moving average price is $8.54 and its 200 day moving average price is $10.03. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market cap of $661.17 million, a P/E ratio of -4.55 and a beta of 0.40.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. As a group, equities research analysts anticipate that UroGen Pharma will post -3.12 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Mark Schoenberg sold 5,162 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the transaction, the insider now directly owns 153,378 shares in the company, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 5.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new position in UroGen Pharma during the fourth quarter worth $1,472,000. Lazard Asset Management LLC acquired a new position in UroGen Pharma during the fourth quarter worth $67,000. Janus Henderson Group PLC acquired a new position in UroGen Pharma during the fourth quarter worth $149,000. ProShare Advisors LLC acquired a new position in UroGen Pharma during the fourth quarter worth $137,000. Finally, Bank of New York Mellon Corp lifted its stake in UroGen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after purchasing an additional 6,430 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.
About UroGen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
